Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 2Completed 2Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × oregovomab × Clear all
NCT00003634 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

National Cancer Institute (NCI)

Phase 2 Unknown
400 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00004064 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡